BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 20152234)

  • 1. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
    Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
    Furenes EB; Arnesen H; Solheim S; Grøgaard HK; Hoffmann P; Seljeflot I
    Thromb Res; 2009 Nov; 124(5):560-4. PubMed ID: 19410278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis.
    Güray U; Erbay AR; Güray Y; Yilmaz MB; Boyaci AA; Sasmaz H; Korkmaz S; Kütük E
    Int J Cardiol; 2004 Aug; 96(2):235-40. PubMed ID: 15262039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
    Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
    Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
    Tziakas DN; Chalikias GK; Parissis JT; Hatzinikolaou EI; Papadopoulos ED; Tripsiannis GA; Papadopoulou EG; Tentes IK; Karas SM; Chatseras DI
    Int J Cardiol; 2004 Apr; 94(2-3):269-77. PubMed ID: 15093992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
    Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of doxycycline on the expression of matrix metalloproteinase and tissue inhibitor of MMP in myocardium after acute myocardial infarction: an animal experiment with rats].
    Zhang P; Yang YJ; Chen X; Ruan YM; Zhou YW; Tian Y; Chen ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(15):1288-93. PubMed ID: 15387968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
    Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
    Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease.
    Opstad TB; Pettersen AA; Weiss TW; Akra S; Øvstebø R; Arnesen H; Seljeflot I
    Clin Chim Acta; 2012 Jan; 413(1-2):113-20. PubMed ID: 21963461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
    Fiotti N; Altamura N; Orlando C; Simi L; Reimers B; Pascotto P; Zingone B; Pascotto A; Serio M; Guarnieri G; Giansante C
    Int J Cardiol; 2008 Jul; 127(3):350-7. PubMed ID: 17706812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.